Nexus -
info_outline
Stay signed in to save your points and redeem your rewards at Nexus

Your Rewards are Waiting!

Stay signed in to save the points you've earned. Click on the points to redeem your rewards at Nexus before they expire.

Login In Now
Star Biz7

The great recovery

By DOREENN LEONG

IT was a bitter pill for investors when Pharmaniaga Bhd plunged into Practice Note 17 (PN17) status in 2023 after a massive Covid-19 vaccine impairment shattered earnings and eroded market confidence.

Few expected the government-linked pharmaceutical group to recover so quickly.

Get 20% OFF The Star Digital Access

Monthly Plan

RM 13.90/month

RM 11.12/month

Billed as RM 11.12 for the 1st month, RM 13.90 thereafter.

Best Value

Annual Plan

RM 12.33/month

RM 9.87/month

Billed as RM 118.40 for the 1st year, RM 148 thereafter.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!
Pharmaniaga , Biopharmaceuticals , InsulinManufacturing , HealthcareSector , VaccineDevelopment , DiabetesCare , HealthcareSecurity , TurnaroundStory

Next In Business News
Ensuring a smooth drive�
Store expansion to fuel MyNews growth
Arm tokens in hand, what now?�
Why some homes rot faster
Covered but still exposed
Auction market rising
Perlis Inland Port to contribute to US$30bil Malaysia-Thailand trade target
Oriental Kopi’s quick profit dip highlights challenges in F&B sector
Sobering times for alcohol industry
AI investment play requires careful portfolio selection

Trending in Business

Others Also Read

Load more

Copyright © 1995- Star Media Group Berhad [197101000523 (10894-D)]

Best viewed on Chrome browsers.